Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Meropenem
Drug ID BADD_D01393
Description Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death. In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and [DB12107] and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.
Indications and Usage For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (excluding vancomycin-resistant isolates), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis and Peptostreptococcus species; complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. Also for use in the treatment of bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (b-lactamase and non-b-lactamase-producing isolates), and Neisseria meningitidis.
Marketing Status approved; investigational
ATC Code J01DH02
DrugBank ID DB00760
KEGG ID D02222; D08185
MeSH ID D000077731
PubChem ID 441130
TTD Drug ID D0O5FY
NDC Product Code 81962-000; 68001-447; 55150-208; 0781-3098; 81962-001; 63323-508; 63323-507; 68083-147; 0409-1391; 70121-1453; 70594-076; 44567-400; 55150-207; 0409-1390; 0781-3000; 52946-0839; 68001-324; 44567-145; 68083-146; 0409-0222; 70121-1454; 72572-415; 72572-416; 38217-0020; 38217-0021; 68001-323; 68001-446; 70278-103; 0409-3412; 70278-104; 70594-075; 44567-401; 44567-146
UNII FV9J3JU8B1
Synonyms Meropenem | 3-(5-Dimethylcarbamoylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid | Merrem | Ronem | Penem | SM 7338 | SM-7338 | SM7338
Chemical Information
Molecular Formula C17H25N3O5S
CAS Registry Number 96036-03-2
SMILES CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Shock24.06.02.0020.000097%Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.0030.000194%Not Available
Skin reaction10.01.03.019; 23.03.03.0130.000073%Not Available
Skin ulcer24.04.03.007; 23.07.03.003--
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.000049%Not Available
Status epilepticus17.12.03.0050.000097%Not Available
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.0050.000049%
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.0070.000194%Not Available
Tachypnoea22.02.01.0140.000049%Not Available
Tenderness08.01.08.0050.000049%Not Available
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.0020.000486%Not Available
Thrombocytosis01.08.02.001--Not Available
Thrombophlebitis24.01.02.001--Not Available
Toxic encephalopathy17.13.01.004; 12.03.01.0270.000049%Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Unresponsive to stimuli17.02.05.0310.000097%Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urticaria10.01.06.001; 23.04.02.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vomiting07.01.07.003--
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
Wheezing22.03.01.0090.000073%
White blood cell count decreased13.01.06.012--
Tubulointerstitial nephritis20.05.02.0020.000194%Not Available
Coronary artery dissection02.02.01.004; 12.02.01.035; 24.02.02.0010.000073%Not Available
Hypereosinophilic syndrome01.02.04.0050.000146%Not Available
The 8th Page    First    Pre   8 9 10    Next   Last    Total 10 Pages